Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

By Global News Feed

ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.

Go here to see the original:
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

PharmAla Announces Private Placement and Concurrent Debt Settlement

By Global News Feed

VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce its intention to complete a non-brokered private placement offering of units of the Company (each, a “Unit”) at a price of $0.18 per Unit for aggregate gross proceeds of up to $750,000 (the “Offering”). It is anticipated that the Offering will be funded solely by a small group of long-term shareholders, known to the Company, who have expressed commitments.

Read the original:
PharmAla Announces Private Placement and Concurrent Debt Settlement

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

By Global News Feed

NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that TALEN-mediated intron editing of hematopoietic stem and progenitor cells (HSPCs) enables transgene expression restricted to the myeloid lineage. This approach could unlock new therapeutic avenues for the treatment of inborn metabolic diseases as well as neurological diseases that require delivery of therapeutics to the brain.

Go here to read the rest:
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

CARBIOS announces fiscal-year 2023 financial results and confirms 2024 calendar for industrial and commercial roll-out

By Global News Feed

Clermont-Ferrand, France, April 11, 2024 (6:45 a.m. CEST) - CARBIOS (Euronext Growth Paris: ALCRB), a biotech company developing and industrializing biological solutions to reinvent the life cycle of plastic and textiles, today reported its operating and financial results for the financial year 2023. The financial statements as of December 31, 2023, were approved by the Company’s Board of Directors at their meeting on April 10, 2024.

Go here to see the original:
CARBIOS announces fiscal-year 2023 financial results and confirms 2024 calendar for industrial and commercial roll-out

Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer’s disease diagnosis

By Global News Feed

Basel, 11 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Elecsys pTau217 assay received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This blood test, which is being developed in collaboration with Eli Lilly and Company, will be used to help identify the presence or absence of amyloid pathology in individuals, which can help ensure they are able to receive appropriate care. This may include participation in clinical trials or access to approved disease-modifying therapies. If approved, the test could help rapidly broaden access to a more timely and accurate diagnosis and potentially mitigate the impact of Alzheimer’s disease on people and society.

Read this article:
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis

Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024

By Global News Feed

Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its Full-Year 2023 Financial Results on April 18, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.

Continued here:
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024

Paralyzed man who can walk again shows potential benefit of stem cell therapy – ABC News

By Stem Cell Clinic

This page either does not exist or is currently unavailable.

From here you can either hit the "back" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.

STATUS CODE: 500

Go here to read the rest:
Paralyzed man who can walk again shows potential benefit of stem cell therapy - ABC News